This is a working overview of Angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-27. Anything still debated is marked as such rather than presented as settled.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Stored desiccated before use |
| Recommended storage | -20 °C | Protect from light and moisture |
| Common stock solvent | Dimethyl sulfoxide | Aqueous solubility may be limited |
| Purity method | Reverse-phase HPLC | Reports percent purity and impurities |
| Identity method | Mass spectrometry | Confirms molecular mass |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
=== Construction === Spent diatomaceous earth from the brewing process can be added to ceramic mass for the production of red bricks with higher open porosity. Diatomaceous earth is considered a prominent inorganic non-metallic material that can be used for the production of various ceramics, including production of porous ceramics under low temperature hydrothermal technology.
=== Relationship with Jeffrey Epstein === On January 30, 2026, the United States Department of Justice released a tranche of around 3,000,000 documents from an archive previously collected by the FBI in relation to their investigation into Jeffrey Epstein's various child sex crimes. It revealed that Ariely had a longstanding relationship with Epstein, including having visited him at his New York home on several occasions. One of the documents is an image of an email from Ariely to Epstein, in which he requests the name and email of a "redhead" that Epstein had previously introduced to him. Following claims made about his association with Epstein, Ariely published a response in the student newspaper Duke Chronicle, stating, "...the contact I had with Jeffrey Epstein was infrequent, largely logistical, often mediated by assistants". He also explained that he had met the woman at a conference, assumed she was a colleague of his, and had an intellectual conversation with her, but he did not recall ever meeting her again. The New York Times subsequently reported further on Ariely's relationship with Epstein, including Ariely asking Epstein for funding for a film he was making in 2014, seeking travel tips, and accepting a tour of a Ferrari factory arranged by Epstein. Ariely is named 636 times in the Epstein files, although many of the mentions are in threads of emails where Epstein's assistant scheduled multiple meetings each day.
== Description == The Red Savina typically measures 2 inches by 1.5 inches (5 x 3.5 cm), and is described by cultivators as a "wrinkled" fruit with a "Chinese lantern" shape. Unlike a conventional orange habanero, the Red Savina is distinctively dark red, and may have been bred using spicy red mutations of habanero. Until 2011, it was protected by the U.S. Plant Variety Protection Act (PVP #9200255).
== Research == Her achievements include the discovery of adaptins, which are specific proteins that manage cell-trafficking to ensure the correct cell cargo is transported to the right location. She also discovered different combinations of adapting, when together with clathrin, form a coat around vesicles that bud from intracellular membranes and act as transporters for protein packages to be distributed in the cell. She also developed the technique "knock sideways," which inactivates proteins in seconds. After finishing her postdoc, she was able to start her own lab. Her main focus was to learn more about the AP protein in depth. She had to also work with DNA because in order to characterize the complexes thoroughly, she needed to clone the subunits. Robinson and her lab managed to find another AP complex, AP-3, which interacts with lysosomal membrane proteins such as LAMP1. AP-3 also interacts with tyrosinase, which is a key enzyme in melanin biosynthesis, so AP-3 is important for tyrosinase trafficking to premelanosomes. As of 2016 Robinson has a lab at Cambridge Institute for Medical Research. She specifically works with coated vesicles. The best-characterized coated vesicles are the clathrin-coated vesicles (CCVs). The coats on CCVs are primarily of clathrin, adaptor protein (AP) complexes, and alternative adaptors. Her working hypothesis is that for each trafficking pathway, there are a number of different adaptors, each of which is recruited independently onto the appropriate membrane.
Sources: en.wikipedia.org
For services to Child Road Safety. Kenneth Fitzpatrick. Lifeboat Operations Manager, Porthdinllaen Lifeboat Station, Royal National Lifeboat Institution. For services to Maritime Safety. Barry Flack. For services to the Jewish Community in the London Borough of Barnet. Margaret Elizabeth Flanagan. Member, Inner Wheel Club of Ballymena. For voluntary services to the community in Ballymena, County Antrim. John Campbell Forrester. President and Poppy Appeal Organiser, Driffield Branch, Royal British Legion. For voluntary service to Veterans in East Yorkshire. Claire Forsythe. Duke of Edinburgh's Award Officer, Probation Board for Northern Ireland. For services to the Rehabilitation of Offenders. Susan Joan Foster. For voluntary service in Hampshire. Richard Charles Fowler. Library Lead, Harbury Community Library, Warwickshire. For services to Libraries. Dr Jennifer Ann Frow. Volunteer, Bewdley Tennis Club. For services to Lawn Tennis in Worcestershire. Robert Francis Fyfe. Chair and Director, Runway Theatre Company. For services to the Arts and to the community in Glasgow. Melanie Jane Gardner. Fine and Decorative Arts Curator, Tullie House Museum, Carlisle. For services to Arts and Culture in Cumbria. Joseph William Garvey. For services to the community in County Armagh. Peter William Garwood. For services to the community in Barrow-in-Furness, Cumbria. Christine Frances Gatfield. Founder, Dove Cottage Day Hospice. For services to the Terminally Ill. Patricia Mary Gaywood. Membership Secretary, The Forty Club. For voluntary service to Cricket. Andrew Gell.
== Controversy == At the 68th AACC Annual Scientific Meeting in 2016, Elizabeth Holmes, CEO and founder of Theranos, spoke at what AACC described as a “special session.” Holmes, who the Centers for Medicare and Medicaid Services (CMS) had recently been banned from owning, operating or directing a blood testing service for a period of two years, was invited to present scientific data on her company's much discussed Edison device. Instead, Holmes took the opportunity to unveil a new product dubbed miniLab. Several people on the Theranos scientific advisory board were members of the association.
The Bailey peptide synthesis is a name reaction in organic chemistry developed 1949 by J. L. Bailey. It is a method for the synthesis of a peptide from α-amino acid-N-carboxylic acid anhydrides (NCAs) and amino acids or peptide esters. The reaction is characterized by short reaction times and a high yield of the target peptide. The reaction can be carried out at low temperatures in organic solvents. The residues R1 and R2 can be organic groups or hydrogen atoms, R3 is the used amino acid or peptide ester:
Sources: en.wikipedia.org
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.
Mass spectrometry is commonly used to confirm molecular mass, while reverse-phase HPLC assesses purity. Some laboratories also use nuclear magnetic resonance for structural verification. These methods are standard for research peptides.
Aqueous solubility can be limited and varies by batch and salt form. Dimethyl sulfoxide is often used for stock solutions. Supplier documentation or a solubility test can clarify behavior for a given lot.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.